Navigation Links
Agendia Signs Contract with Blue Shield of California
Date:1/5/2012

IRVINE, Calif. and AMSTERDAM, Jan. 5, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company has signed a contract with Blue Shield of California, making Agendia an in-network provider. The move paves the way for future in-network coverage for MammaPrint® and other Agendia tests by Blue Cross affiliates across the United States. Developed and commercialized by Agendia, MammaPrint is the keystone of the company's Symphony™ suite of breast cancer assays, and the first and only molecular breast cancer recurrence assay cleared by the U.S. Food and Drug Administration (FDA) in February 2007. The gene expression signature assay is used by physicians as a prognostic and predictive tool to identify patients whose risk of metastases is high, requiring chemotherapy, and those at a low risk of metastases, who can be treated just as effectively with other therapies that cause fewer adverse side effects.

"Agendia's contract with Blue Shield of California not only provides more patients with access to MammaPrint, but it also has the potential to open the door to future coverage across the Blue Shield network," said Agendia's CEO, David Macdonald.

As a result of the contract, Agendia will be reimbursed for its MammaPrint test at an in-network rate, benefiting patients by reducing any financial obligation they might carry. Several major payers, including Medicare, Humana, United and others have issued medical coverage policies for MammaPrint. In addition to Blue Shield of California, Agendia has entered contracts with Palmetto, Humana, Coventry and several national PPO plans.

About Agendia:
Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:

Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300
E-mail: todd@ricochetpr.com


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
2. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
3. Agendia Successfully Completes Bi-Annual FDA Inspection
4. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
5. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
6. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
7. Agendia Raises US $23 Million in Series E Financing
8. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
9. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
10. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
11. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that ... 510(k) for sale in the United States. These components expand the capabilities of ... With one-level sales beginning in October of 2015, the company has seen significant sales ...
(Date:4/28/2016)... , April 28, 2016 ... company reports the Company,s CEO  was featured in ... Accelerators Enter When VCs Fear To Tread: ... Leader magazine is an essential business ... everything from emerging biotechs to Big Pharmas. Their ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
Breaking Biology News(10 mins):